Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-18. Numbers and descriptions here follow the published literature rather than marketing material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
The fruit is a hairy pod that grows in clusters of three to five, each pod is 3–8 cm (1–3 in) long and usually contains two to four (rarely more) seeds 5–11 mm in diameter. Soybean seeds come in a wide variety of sizes and hull colors such as black, brown, yellow, and green. Variegated and bicolored seed coats are also common.
On June 26, 2025, Pritzker announced he would seek a third term as governor. With incumbent Lieutenant Governor Juliana Stratton running for U.S. Senate, Pritzker chose former state representative Christian Mitchell as his running mate. Pritzker and Mitchell ran unopposed in the March Democratic primary, winning 100% of the vote. Pritzker faces the Republican nominee, former state senator Darren Bailey, in a rematch in the November general election. Should Pritzker win, he will be first Illinois governor to win a third term since Jim Thompson in 1986, and the first Democrat to do so in Illinois history.
=== Mechanism of action === Isotretinoin's exact mechanism of action is unknown, but several studies have shown that isotretinoin induces apoptosis (programmatic cell death) in various cells in the body. Cell death may be instigated in the meibomian glands, hypothalamic cells, hippocampus cells and—important for treatment of acne—in sebaceous gland cells. Isotretinoin has a low affinity for retinoic acid receptors (RAR) and retinoid X receptors (RXR), but may be converted intracellularly to metabolites that act as agonists of RAR and RXR nuclear receptors. One study suggests the drug amplifies production of neutrophil gelatinase-associated lipocalin (NGAL) in the skin, which has been shown to reduce sebum production by inducing apoptosis in sebaceous gland cells, while exhibiting an antimicrobial effect on Cutibacterium acnes. The drug decreases the size and sebum output of the sebaceous glands. Isotretinoin is the only available acne drug that affects all four major pathogenic processes in acne, which distinguishes it from alternative treatments (such as antibiotics) and accounts for its efficacy in severe, nodulocystic cases.
Histology image: 09601loa – Histology Learning System at Boston University – "Digestive System: Oral Cavity and Teeth – lip, oral mucosa" Histology image: 95_04 at the University of Oklahoma Health Sciences Center – "Lip" Histology image: 95_07 at the University of Oklahoma Health Sciences Center – "Lip" Common Dental and Oral Mucosal Disorders, Duke University at https://web.archive.org/web/20160303221658/http://pamodules.mc.duke.edu/Oral_Health/Print.asp?CourseNum=1&LessonNum=3
α A + β B ⇌ σ S + τ T The equilibrium concentration position of a reaction is said to lie "far to the right" if, at equilibrium, nearly all the reactants are consumed. Conversely the equilibrium position is said to be "far to the left" if hardly any product is formed from the reactants. Guldberg and Waage (1865), building on Berthollet's ideas, proposed the law of mass action:
Sources: en.wikipedia.org
1 March to 8 May The 4th Marine Regiment launched Operation Purple Martin against three PAVN regiments operating near the Vietnamese Demilitarized Zone (DMZ). The operation results in 347 PAVN killed and approximately 100 Marines killed.
The signal is detected by a P2X receptor; these receptors occur across the animal kingdom in phyla including sponges, cnidaria, placozoa, mollusca, arthropoda, and chordata, and in both fungi and green plants. Such sharing between eukaryote groups implies that these damage response mechanisms are ancient and have been conserved in evolution. Thibaut Brunet and Detlev Arendt propose that the last eukaryotic common ancestor (LECA) possessed a calcium-based wound healing response. They argue that the mechanism's purpose was to detect and heal a potentially fatal opening in the cell membrane. They propose that it worked by detecting an inflow of calcium ions, which provoked a contraction in muscle-like actomyosin proteins. This in turn caused vesicles to fuse with the cell membrane (exocytosis), healing the opening and preventing the cell from splitting open.
=== Government, economic, and military institutions === The end of the Cold War also coincided with the end of apartheid in South Africa. Declining Cold War tensions in the later years of the 1980s meant that the apartheid regime was no longer supported by the West because of its anticommunism, but it was now condemned with an embargo. In 1990, Nelson Mandela was freed from prison and the regime began steps to end apartheid. This culminated in the first democratic elections in 1994, which resulted in Mandela being elected as President of South Africa. Socialist and communist parties around the world saw drops in membership after the Berlin Wall fell, and the public felt that free-market ideology had won. Libertarian, neoliberal, nationalist and Islamist parties, on the other hand, benefited from the fall of the Soviet Union. As capitalism had "won," as people saw it, socialism and communism in general declined in popularity. Social democrats in Scandinavia privatized many of their institutions in the 1990s, and a political debate on modern economics was reopened. Scandinavian nations are often now seen as social democrat (see Nordic model). It has been posited by some scholars that the end of communism as a global force in the post–Cold War era allowed neoliberal capitalism to become the dominant global system, which has resulted in rising economic inequality.
==== I. Blood Brain Barrier Disruption ==== The brain is protected by tight junctions in the endothelial cell wall in the capillaries, known as the blood-brain barrier (BBB). The BBB strictly regulates what passes into the brain from the blood, and while this function is highly desirable in healthy individuals, it also poses a barrier for therapeutics to enter the brain for cancer patients. Ultrasound was shown to disrupt the blood brain barrier in the mid 20th century, and in the early 2000's, microbubbles were shown to assist in a temporary permeabilization. Since then, ultrasound and microbubble therapy has been used to deliver therapeutics to the brain. As BBB disruption with ultrasound and microbubble treatment has shown to be a safe and promising treatment pre-clinically, two clinical trials are testing delivery of doxorubicin and carboplatin with microbubbles to increase drug concentration locally.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.